{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:31:23Z","timestamp":1793496683135,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The aim of this study was to evaluate changes in body weight, liver weight, blood glucose, liver injury markers, pro-inflammatory factors and oxidative stress marker levels in obese mice with HFD induced NAFLD after semaglutide use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>The 24 C57BL6J mice were randomly divided into three groups (NCD, HFD and Sema) for the assessment of metabolic status, inflammatory factor and oxidative stress marker levels, liver histopathology in mice. Liver metabolomics was determined by liquid chromatography\/mass spectrometry (LC-MS) method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mice body weight, liver weight, blood glucose, TG, TCHO, LDL and pro-inflammatory factors were significantly reduced after semaglutide. Meanwhile, semaglutide increased the SOD level. Semaglutide treatment significantly improved the pathological changes such as hepatocyte steatosis, balloon degeneration and lymphoid foci by HE. It also significantly reduced lipid droplet by Oil Red O. The mitochondria were swollen, the volume increased, the cristae were partially broken and reduced, the intramembrane matrix was partially dissolved, and the mitophagy structure was visible in the visual field. There were 6 metabolites down-regulated and 2 metabolites significantly up-regulated after semaglutide treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Semaglutide can reduce blood glucose level and liver fat accumulation and play an anti-inflammatory role in advanced NAFLD that due to the effects of HFD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1046130","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T06:29:40Z","timestamp":1670567380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":79,"title":["Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model"],"prefix":"10.3389","volume":"13","author":[{"given":"Shu","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S62831","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2174\/1570161115666170621080228","article-title":"A critical approach of guideline therapeutic recommendations for NAFLD","volume":"16","author":"Djordjevic","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"154413","DOI":"10.1016\/j.metabol.2020.154413","article-title":"Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? the epidemic of the 21st century in search of the most appropriate name","volume":"113","author":"Polyzos","year":"2020","journal-title":"Metabolism: Clin Exp"},{"key":"B5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism: Clin Exp"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.09.025","article-title":"Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"137","author":"Bifari","year":"2018","journal-title":"Pharmacol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"New Engl J Med"},{"key":"B9","article-title":"Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases","volume":"9","author":"Safaei","year":"2016","journal-title":"Gastroenterol Hepatol bed to bench"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071661","article-title":"Nephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease","volume":"10","author":"Dalb\u00f8ge","year":"2022","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3177\/jnsv.59.56","article-title":"Intragastric administration of allyl isothiocyanate reduces hyperglycemia in intraperitoneal glucose tolerance test (IPGTT) by enhancing blood glucose consumption in mice","volume":"59","author":"Mori","year":"2013","journal-title":"J Nutr Sci vitaminol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0815-3","article-title":"Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats","volume":"55","author":"Xu","year":"2010","journal-title":"Digestive Dis Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3760\/j.issn:1007-3418.2005.05.017","article-title":"[Expression of uncoupling protein 2 and its relationship to the content of adenosine triphosphate in the nonalcoholic fatty livers of rats fed a high-fat diet]","volume":"13","author":"Fan","year":"2005","journal-title":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14293","article-title":"Aucubin inhibited lipid accumulation and oxidative stress via Nrf2\/HO-1 and AMPK signalling pathways","volume":"23","author":"Shen","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.45.773","article-title":"Lipid alterations in the liver and serum of rats in histidine-excess and copper deficiency","volume":"45","author":"Aoyama","year":"1999","journal-title":"J Nutr Sci vitaminol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2019.10.017","article-title":"Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate alzheimer's disease patients with APOE4(-\/-): A double-blind, randomized, placebo-controlled crossover trial","volume":"39","author":"Xu","year":"2020","journal-title":"Clin Nutr (Edinburgh Scotland)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.12.013","article-title":"Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice","volume":"69","author":"Honda","year":"2017","journal-title":"Metabolism: Clin Exp"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1558","article-title":"The selective peroxisome proliferator-activated receptor gamma modulator CHS-131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis","volume":"4","author":"Perakakis","year":"2020","journal-title":"Hepatol Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220510","article-title":"Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation","volume":"22","author":"Buchman","year":"1995","journal-title":"Hepatol (Baltimore Md.)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/0148607101025005260","article-title":"Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial","volume":"25","author":"Buchman","year":"2001","journal-title":"JPEN. J parenteral enteral Nutr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5163","article-title":"LPS-induced TNF-\u03b1 factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease","volume":"6","author":"Ceccarelli","year":"2015","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218414","article-title":"Liver regeneration after hepatectomy and partial liver transplantation","volume":"21","author":"Yagi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28953","article-title":"Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease","volume":"65","author":"Hall","year":"2017","journal-title":"Hepatol (Baltimore Md.)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/B978-0-12-394300-2.00002-8","article-title":"The leukotrienes: immune-modulating lipid mediators of disease","volume":"116","author":"Di Gennaro","year":"2012","journal-title":"Adv Immunol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1046130\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T06:29:43Z","timestamp":1670567383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1046130\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":27,"alternative-id":["10.3389\/fendo.2022.1046130"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1046130","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"article-number":"1046130"}}